Glaucoma and Cataract Surgery Market, By Product Type (Glaucoma Surgery Device (Implant & Stent, Glaucoma Drainage, Glaucoma Laser Device) and Cataract Surgery Device (Intraocular Lens, Ophthalmic Viscoelastic Device, Phacoemulsification System)), By Surgery Type (Glaucoma Surgery (Conventional Glaucoma Surgery, and Minimally Invasive Glaucoma Surgery) and Cataract Surgery (Phacoemulsification, Extracapsular Cataract Extraction (ECCE) surgery, Femtosecond Laser Surgery, and Others)), By End User (Hospital, Ophthalmology Clinic, Outpatient Surgery Center), and By Region (North America, Europe, Asia Pacific, Latin America and Middle East & Africa)) - Trends, Analysis and Forecast till 2034

Glaucoma and Cataract, eye related disorder are caused by damage to the optic nerve that carries information from the eye to the brain. Minimally Invasive Glaucoma Surgery (MIGS) includes a broad range of procedures and devices aiming lower IOP (Intra Ocular Pressure) in a safer manner with less surgical risk than other established procedures. Glaucoma and cataract are two different conditions but can coexist together and requires surgical interventions for treatment. The blurriness of vision due to clouding of the lens is known as cataract. Delay or if left untreated, the patient may lose vision and become blind forever in both the eye disorder. Cataract surgery is the removal of clouded natural lens, and involves implantation of intraocular lens. Cataracts and glaucoma is the leading cause of blindness, affect some 120 Mn people worldwide.

Rising Geriatric population

Due to increase in geriatric population with glaucoma disorder and advancement in technologies in ophthalmic surgical devices are the major driving factors responsible for the growth of global glaucoma and cataract surgery market. Age related problem, diabetes and other diseases results in eye related disorders can enhance the growth of target market. Increasing demand for minimal invasive surgical procedures and government initiatives such as favorable reimbursement policies in developed countries increases the growth of the target market.

Technological Advancements and Rapid Expansion

Technological development such as in eye drops, which are the primary glaucoma control measure. Pharmaceutical and biotech businesses are also investing in the creation of novel products boosting the glaucoma and cataract surgery market. The most common medications used to treat glaucoma and cataract today include alpha-adrenergic agonists, beta-blockers, carbonic anhydrase inhibitors, prostaglandin analogues, and combinations of these drugs. Introduction of laser therapy might also boost the targeted market.

Customized surgical planning

Rapid expansion of ophthalmological industries and increasing incidences of eye related problems to boost the glaucoma and cataract surgery market. Surgeons are increasingly tailoring glaucoma and cataract surgery to individual patient needs through the use of advanced diagnostic tools and technologies. This includes optimizing incision placement, lens selection, and astigmatism correction, increasing patient satisfaction boosts the glaucoma and cataract surgery market.

Restraints of the Glaucoma and Cataract Surgery Market:

Complications association with cultivation of Biotech seeds

Shortage of qualified experts, high cost of surgery and less awareness regarding eye related surgeries hiders the glaucoma and surgery market.

Latest Trends

Advancements in surgery methods such as Minimally Invasive Glaucoma Surgery (MIGS) procedures have been gaining popularity as they offer a less invasive alternative to traditional glaucoma surgeries. These procedures are often performed concurrently with cataract surgery.

Glaucoma and Cataract Surgery Market is segmented based on Product Type, surgery type, End-user, and Region.

Product Type Insights

On the basis of Product Type, the target market is segmented into Glaucoma Surgery Device (Implant & Stent, Glaucoma Drainage, and Glaucoma Laser Device) and Cataract Surgery Device (Intraocular Lens, Ophthalmic Viscoelastic Device, and Phacoemulsification System).

Surgery Insights

On the basis of Surgery, the target market is segmented into Glaucoma Surgery (Conventional Glaucoma Surgery, and Minimally Invasive Glaucoma Surgery) and Cataract Surgery (Phacoemulsification, Extracapsular Cataract Extraction (ECCE) surgery, Femtosecond Laser Surgery, and Others)

End-User Insights

On the basis of End-user, the target market is segmented into Hospital, Ophthalmology Clinic, and Outpatient Surgery Center.

Regional Insights:

On region the target market is segmented into North America, Europe, Asia Pacific, Latin America, and Middle East & Africa.

• North America market is estimated to witness a significantly high revenue share over the forecast period due to rising growth of geriatric population, increasing burden of diseases such as diabetes, one of the major cause of glaucoma and cataract is due to lifestyle changes, prevalence of obesity boosts the glaucoma and cataract surgery market in the region over the forecast period.
• Asia Pacific market is estimated to witness a fastest revenue share over the forecast period due to increasing geriatric population, emerging key players and prevalence of diabetes and obesity. Lifestyle changes correlating with glaucoma and cataract are altogether boosting the glaucoma and cataract surgery market in the region.

Report Scope:

Segments Covered in the Report:

This report forecasts revenue growth at global, regional, and country levels and provides an analysis of the latest industry trends and opportunities in each of the sub-segments from 2024 to 2034.

The key players operating the Glaucoma and Cataract Surgery Market includes

• Alcon, Inc. (Novartis AG)
• New World Medical, Inc.
• Johnson & Johnson Pvt Ltd.
• Bausch & Lomb, Inc.
• Valeant Pharmaceuticals International, Inc.,
• Topcon Corporation
• Lumenis Ltd.
• Allergan plc.
• Carl Zeiss Meditec Incorp.
• Ellex Medical Lasers Ltd.
• Abbott Laboratories, Inc.

Recent Development:

 The New Launched Product News,

• In March 2023, Sight Sciences Inc. announced the United States launch of its Ergo-Series of OMNI Surgical System, a technology that facilitates surgeons’ ability to perform minimally invasive, implant-free glaucoma procedures in adults with primary open-angle glaucoma. According to the company, its surgical system enables a minimally invasive glaucoma surgery (MIGS) that addresses all 3 known points of resistance in the aqueous outflow system: the trabecular meshwork, Schlemm’s canal, and the collector channels. It can be used before, in combination with, or following cataract surgery.
• In April 2023, Bausch and Lomb Corp. announced the U.S. launch of StableVisc cohesive ophthalmic viscosurgical device (OVD) as well as TotalVisc Viscoelastic System. According to the company, these options provide eye surgeons with new options for dual-action protection during cataract surgery.
• In December 2023, Johnson & Johnson Vision, a global eye health company, launched new intraocular lens for cataract surgery and laser vision correction equipment in Korea. TECNIS PureSee IOL for cataract surgery and the ELITA Femtosecond Laser System for corneal refractive laser vision correction. ELITA is Johnson & Johnson Vision's first new corneal refractive laser vision correction device in 22 years.